Home › Myasthenia Gravis › Michigan
Myasthenia Gravis clinical trials in Michigan
12 studies for Myasthenia Gravis are looking for participants at sites in Michigan.
Cities in Michigan
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
- Henry Ford Hospital, Detroit
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Sep 25, 2026 · NCT07217587ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
- Henry Ford Health System, Detroit
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT07294170ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
- Henry Ford Health Systems, Detroit
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT07284420A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)
- TG Therapeutics Investigational Trial Site, Farmington Hills
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07673744A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
- TG Therapeutics Investigational Trial Site, Ann Arbor
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06680037Study of Aritinercept in Patients With Generalized Myasthenia Gravis
- Aurinia Investigational Site, Dearborn
- Aurinia Investigational Site, Flint
RecruitingPhase 1/2
Ages 18 to 85 · All sexes · Updated Aug 3, 2026 · NCT07596901A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
- C.S. Mott Children's Hospital, Ann Arbor
RecruitingPhase 2/3
Ages 2 to 17 · All sexes · Updated Jul 31, 2026 · NCT05265273Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
- Site Number - 1026, Detroit
- Site Number - 1005, East Lansing
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Jul 30, 2026 · NCT07039916A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
- Michigan State University Clinical Center, East Lansing
- Trinity Health - Grand Rapids Hospital, Grand Rapids
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jun 18, 2026 · NCT06456580A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
- Karmanos Cancer Institute, Detroit
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 25, 2026 · NCT06626919Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
- Clinical Trial Site, Lansing
RecruitingObservational study
Ages 18 and older · All sexes · Updated Feb 18, 2026 · NCT04202341A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
- Henry Ford Health System, Detroit
RecruitingObservational study
Ages 18 and older · All sexes · Updated Feb 17, 2026 · NCT06298565From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.